Reach more patients
with more RNA medicines.

We have identified hundreds of novel receptor targets and use these discoveries to advance programs into the clinic. Our preclinical pipeline of cell-targeted medicines includes programs in fibrosis, immunology, and inflammatory disease. Our lead program in fibrosis entered IND-enabling studies in 2025 with an anticipated first in human trial in 2026.